Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    NCT01179217
Show Display Options
Rank Status Study
1 Completed A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia
Conditions: Sickle Cell Anemia;   Sickle ß0-Thalassemia
Interventions: Drug: L-glutamine;   Drug: 100% maltodextrin

Indicates status has not been verified in more than two years